The views expressed here are those of the individual authors and not necessarily those of the JSM sponsors, their officers, or their staff.
Online Program Home
Abstract Details
|
Activity Number:
|
473
|
|
Type:
|
Contributed
|
|
Date/Time:
|
Wednesday, August 1, 2012 : 8:30 AM to 10:20 AM
|
|
Sponsor:
|
Biopharmaceutical Section
|
| Abstract - #305168 |
|
Title:
|
Competing Risk Analysis of PFS Considering Patients Who Switch Therapy Prior to Progression
|
|
Author(s):
|
Lixia Jiao*+
|
|
Companies:
|
Sanofi Aventis
|
|
Address:
|
42 Purcell Road, Bridgewater, NJ, 08807-5628, United States
|
|
Keywords:
|
survival analysis ;
competing risk ;
time to event
|
|
Abstract:
|
Standard survival analysis methods, such as Kaplan Meier curves, log-rank test and Cox proportional hazard model, are widely accepted tools to compare the cause-specific hazards when there is only one event of interest and the time to event and time to censoring are independent. However, competing risks are often encountered in clinical research, where multiple failure types exist and one type of event either precludes the occurrence of another event or fundamentally alters the probability of occurrence of the other event. In the analysis of competing risks data, the standard analysis methods may lead to biased results by treating the competing event as censored at the time this event occurs. This way, it is assumed that the patients failing from a competing risk are no more or less likely to fail from the cause of interest than the patients still at risk beyond this time. The newly deve
|
The address information is for the authors that have a + after their name.
Authors who are presenting talks have a * after their name.
Back to the full JSM 2012 program
|
2012 JSM Online Program Home
For information, contact jsm@amstat.org or phone (888) 231-3473.
If you have questions about the Continuing Education program, please contact the Education Department.